Who pays, who understands, who judges femtech products

A woman in Cairo opens a period tracking app for the first time. She is not thinking about features. She is wondering whether anyone else will see the notification on her phone, whether the Arabic on the screen sounds like a textbook or like her own mother, and whether she can afford what comes next if the app tries to sell her something. That is the real first screen of femtech in a market like Egypt, and it has almost nothing to do with the clinical problem the app was built to solve.

Two Cairo-based companies are building inside this reality. Aziza, a free app for tracking periods and pregnancy, made a deliberate choice to skip the subscription model that funds most health apps elsewhere. Its founder, Nesma Amin, put it plainly: “it did not feel right at all to have a [paid] subscription [model] or any barriers to our features.” For Egyptian women, she points out, children, education and household needs come before health. So the app stayed free. In place of a marketing budget, it built a network of more than seventy student ambassadors who run workshops.

Shemsi, which makes reusable period underwear, faced the opposite problem: a good product that almost nobody could afford on day one. A large pack of disposable pads in Egypt costs about two dollars. A pair of Shemsi’s underwear costs closer to fourteen. It can be reused for up to 300 washes, but the fourteen dollars is due upfront, in a market where most households pay for healthcare out of pocket. Shemsi’s answer was flexible payment, including installment plans, because the obstacle was never whether women understood the product. It was whether they could pay for it in one go.

What the clinical gap hides

Neither company is solving a clinical problem. The tracking science behind a period app is not new. Reusable period underwear is not a technical breakthrough. What both are solving for are three things that sit underneath almost every femtech pitch in this region: money, language and shame. Put simply: who pays, who understands, and who judges. They arrive together, and any one of them can kill a product that works perfectly well on paper.

Money first. A 2019 study by the Egyptian Center for Public Opinion Research (Baseera) found that only one in five Egyptian women are covered by medical insurance. Most healthcare is paid for directly, so a health app’s business model is never just a business model; it is a test of whether the women who need the product most can afford to be its customers.

Egyptian women covered by medical insurance

1 in 5

a large pack of disposable pads

$2

a pair of reusable period underwear, due upfront

$14

washes a pair can last

300

Language next. Medical information is often delivered in fusha, formal Arabic, a register far enough from the Egyptian dialect people speak every day that it reads as clinical rather than personal. The alternative is usually an app built outside the region, which only reaches women comfortable speaking English or talking about their bodies in a particular way. Neither meets most women where they are.

Then shame, which does real commercial damage. The stigma around virginity is a major reason disposable pads still dominate the market. Unmarried women are warned that inserting anything could compromise the hymen, and the disdain for tampons persists even after marriage. Nobody doubts tampons work. Buying one, carrying one, being seen with one: each carries a cost that has nothing to do with absorbency.

The counterargument, and why it doesn’t hold

The obvious pushback is that none of this is a product company’s job. Insurance coverage is a policy question. Dialect versus formal Arabic is a translation detail. Stigma is a cultural problem no founder can fix with a feature.

All of that is true, and none of it changes what happens in the market. A femtech product that ignores insurance coverage builds a demo, not a business, because the women who matter commercially are the eighty percent paying out of pocket. A product that launches in clinical Arabic reaches the clinics and misses the households. A product that treats stigma as someone else’s problem will lose to the one designed around it from day one, the way Aziza designed around cost and Shemsi designed around dignity.

Who owns the problem is a policy question. Whether the product survives it is a business one.

What this means for how femtech gets built and funded

This is the part accelerators and funders underweight when they evaluate femtech in Africa and the Middle East. Scorecards still lean on clinical validation and on feature comparisons with apps built for entirely different markets. They should be scoring for something else: whether a founder has mapped the money, the language and the shame specific to her market, and built a product that survives contact with all three at once.

That is harder to pattern-match than a feature list. It is also the real difference between a femtech product that gets downloaded once and one that becomes part of how women in that market look after themselves.

Femtech in this region does not have an awareness problem or a technology problem; it has a structural one. Aziza and Shemsi, in different ways, show what it looks like to build around it rather than wait for someone else to fix it first.